ArticleGlycobiology2026
Mapping ST3GAL transferase specificities in the glycosylation landscape of N/TERT-1 keratinocytes using Glycogenomics and mass spectrometry.
Article in Glycobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glycan sialylation is vital for proper cellular function and signaling. The six-membered ST3GAL family of sialyltransferases catalyzes the transfer of sialic acid in an α2,3-linkage to galactose residues on the outermost glycan epitopes. Dysregulation of sialyltransferase activity has been linked to diverse pathological processes. To expand our understanding of the substrate specificity and cooperative function of the ST3GAL family enzymes in protein and lipid glycosylation, we systematically analyzed the function of individual ST3GAL enzymes in glycan biosynthesis using a panel of CRISPR/Cas9-engineered human keratinocyte (N/TERT-1) cell lines with single or combined ST3GAL gene knockouts (KO). For protein glycosylation, KO of ST3GAL1 reduced sialylation of type 3 epitopes (Galβ1,3-GalNAc-) on both core 1 and 2 O-glycans, while complete ablation of sialylation was observed for the combined ST3GAL1 and ST3GAL2 KO. ST3GAL2 KO alone had limited effect, but reduced sialylation of specifically core 1 O-glycans. KO of ST3GAL4 and the combined KO of ST3GAL4 and ST3GAL6 reduced sialylation of type 1 and 2 epitopes (Galβ1,3/4-GlcNAc-) on both N- and O-glycans, while no effect was observed for the single KO of ST3GAL6. In GSL glycan biosynthesis, ST3GAL5 regulated lactosylceramide sialylation, as anticipated. ST3GAL2 and ST3GAL6 mediate sialylation of type 3 motifs, whereas ST3GAL3 and ST3GAL6 target type 2 epitopes, with ST3GAL3 exhibiting no discernible preference between type 1 and type 2 substrates. Our findings reveal that glycosyltransferase specificities are shaped by substrate availability, epitope distribution across glycan classes, and enzyme competition, which can only be captured by investigating this within the cellular context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.